Stayble Therapeutics presents at the Life Science Day in Gothenburg March 8 2023
Stayble Therapeutics AB ("Stayble" or "the Company") announces that the Company will participate in the annual Life-Science Day in Gothenburg, Sweden, which takes place on Wednesday, March 8, 2023. Andreas Gerward, CEO of Stayble, will present the company and introduce the newly started project with STA363, for patients suffering from disc herniation.
The Life Science Day is held for the seventh year in a row and attracts relevant industry players such as doctors, policymakers and investors. The event is a full-day conference with company presentations.
Andreas Gerward will present Stayble and give an update on the latest news. Stayble is currently focusing on the continued clinical development of STA363 and is currently conducting a phase IIb study within degenerative disc disease. In addition, the company has recently initiated a new project with STA363, targeting lumbar disc herniation, where the goal is to initiate a clinical phase Ib study in 2023.
The event will take place at the Wallenberg Conference Center, Sahlgrenska Academy, Medicinareberget in Gothenburg on March 8. The full program and more information about the event can be found at www.lifesciencedagen.se. The event is free of charge for visitors.
CEO Andreas Gerward will present Stayble at 17.00. The presentation can be viewed in real-time or later at www.lifesciencedagen.se.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
Mail: andreas.gerward@stayble.se
Phone: +46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. Aimed at patients who are not helped by physiotherapy and painkillers, the treatment is a single injection that is expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is currently conducting a Phase IIb clinical trial in DDD and a Phase Ib trial in LDH.
Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser.